Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in
clonal proliferation of abnormally differentiated hematopoietic cells. In this review …

Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that
accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric …

Abstract Purpose of Review Acute myeloid leukemia (AML) in children remains a
challenging disease to cure with suboptimal outcomes particularly when compared to the …

Simple Summary For almost 40 years, the combination of anthracyclines and cytarabine,
called 3+ 7, has been the standard of induction chemotherapy for the treatment of acute …

Core binding factor acute myeloid leukemia (CBF AML), defined by t (8; 21) or inv (16), is a
subset of favorable risk AML. Despite its association with a high complete remission rate …

Identification of pediatric patients with acute myeloid leukemia (AML) candidates to receive
allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission …

During the past decade, the outcomes of pediatric patients with acute myeloid leukemia
(AML) have plateaued with 5‐year event‐free survival (EFS) and overall survival (OS) of …

KIT is a type-III receptor tyrosine kinase that contributes to cell signaling in various cells.
Since KIT is activated by overexpression or mutation and plays an important role in the …

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease that requires a
multifaceted treatment approach. Although outcomes for low‐risk AML have improved …

Acute myeloid leukemia (AML) is a clinically, morphologically, and genetically
heterogeneous disorder. Like many malignancies, the genomic landscape of pediatric AML …